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ABSTRACT 
Objective: A simple, sensitive, rapid and precise bioanalytical RP-HPLC method was developed for estimation of clopidogrel bisulfate in human plasma. 
Methods: The work was carried out on Shimadzu LC-2010 CHT HPLC system equipped with Waters C18 (250×4.6 mm, 5μ) column with a mobile 
phase containing acetonitrile: methanol: water (75:20:05 v/v/v). The flow rate of mobile phase was 1 ml/min and the detection was carried out at 
225 nm. The retention time of clopidogrel bisulfate was found to be 4.6 min. 
Results: The developed bioanalytical method was found to be linear in the concentration range of 30.76-69.23 µg/ml. The simple regression 
analysis of chromatographic response showed the value of R2= 0.9917. The precision study revealed that the cumulative percentage variation was 
within acceptable limit and accuracy study showed the value of mean percent recovery between 103.60 to 109.80 %. The clopidogrel was stable in 
human plasma at different storage conditions. 
Conclusion: The validation parameters of the method met the acceptance criteria. Sufficient stability of both LQC and HQC was shown to allow for 
completion of sample analysis in clinical trials. From the results, we can conclude that developed bioanalytical method is simple, rapid, accurate, and 
precise and can be used for routine analysis of clopidogrel bisulfate. 
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INTRODUCTION 
Clopidogrel bisulfate is an oral thienopyridine class of antiplatelet 
agent that used to inhibit blood clots in coronary artery disease 
and to prevent myocardial infraction and stroke [1]. It is 
chemically methyl (S)-α-(o-chlorophenyl) 6, 7-dihydrothieno [3, 2-
c] pyridin-5-(4H)-acetate sulphate [2] (fig. 1). It is a prodrug that 
is converted in the liver to an active thiol metabolite, which 
inhibits adenosine diphosphate (ADP) binding to its platelet 
receptor and subsequent ADP-mediated activation of the 
glycoprotein IIb/IIIa complex, thus inhibiting platelet aggregation. 
Clopidogrel irreversibly modifies the ADP receptor, therefore 
platelets are affected for the remainder of their lifespan [3]. 
Clopidogrel should be used with caution in patients receiving 
another drug that increase the risk of bleeding include 
anticoagulants, other antiplatelet and NSAIDs. 
 
 
Fig. 1: Structure of clopidogrel bisulfate 
 
The literature survey revealed that various UV [4, 5] and HPLC [6, 7] 
methods had been reported for the estimation of clopidogrel 
bisulfate either individually or in combination with other drugs. Few 
bioanalytical methods also have been reported using hyphenated 
and UPLC techniques [8-10], which required sophisticated and 
costly instruments. Therefore, an economical RP-HPLC system was 
used to develop a simple bioanalytical method for estimation of 
clopidogrel bisulfate and validate as per USFDA guideline [11]. 
MATERIALS AND METHODS 
Chemicals and reagents 
A sample of clopidogrel bisulfate was supplied by Ipca Laboratory 
Ltd. Mumbai. Methanol and acetonitrile of HPLC grade were 
obtained from Merck India Ltd. Mumbai. Water is purified by 
purification system for HPLC, ELGA Purelab UHQ. The human 
plasma was procured from Smt. Kashibai Navle General Hospital 
Blood Bank, Pune. (Approval no. 4444, Seq. no. 40SV8605). 
Instrumentation 
Chromatographic separation of the drug was performed on 
Shimadzu LC-2010 CHT equipped with LC solution software with UV 
detector. Separation was attained using Waters C18 column. 
Shimadzu ATY 224 Electronic balance was used for weighing. The 
Remi C24BL ultracentrifuge and Remi CM 101 cyclomixer were used 
for sample preparation. 
Preparation of stock solution 
Clopidogrel bisulfate 100 mg API powder was accurately weighed 
and transferred in 100 ml volumetric flask. The drug was dissolved 
and diluted up to mark with methanol. This solution was further 
diluted to get 100 µg/ml of clopidogrel bisulfate. 
Preparation of mobile phase 
The mobile phase was prepared by mixing of acetonitrile, methanol and 
water in the ratio of 75:20:05 v/v/v and filter through 0.45µ membrane 
filter. The mobile phase was sonicated in an ultrasonic bath for 10 min. 
Sample preparation and extraction  
Clopidogrel from the plasma was extracted using protein precipitation 
technique [12-14]. Frozen human plasma was thawed to ambient 
temperature. Aliquots of 400 μl plasma were taken into eppindorf tube 
and 200 μl of stock solution was added and the plasma proteins were 
precipitated by using methanol. The tube was vortexed for 1 min and 
the solution was centrifuged at 5 °C, 8000 rpm for 10 min. The 
supernant was taken and transferred to HPLC vials. 
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Method validation 
The method performance was evaluated for accuracy, precision, linearity 
and stability during various stress conditions including freeze-thaw 
stability, stock solution stability and short-term stability [15]. 
Linearity and range 
The working solution of various concentrations was injected under 
the operating chromatographic conditions and peak area of each 
concentration were calculated at 225 nm. The calibration curves 
were constructed using simple linear regression between peak area 
and corresponding concentration (fig. 4). The range of solution has 
been decided according to a correlation coefficient of the regression 
equation [16, 17]. 
Accuracy  
The accuracy of the method was performed by calculating % 
recovery for the different concentration levels of the drug. The 
samples of three concentration levels were prepared as a low-
quality control, medium quality control and high-quality control by 
the standard addition method. 
Precision  
The precision of this method was evaluated by the % CV at different 
concentration levels corresponding to LQC, MQC and HQC. The 
intraday and interday precision were evaluated in 3 replicate 
batches of different concentrations (38.46, 53.84, 69.23 µg/ml). 
Stability studies 
The stability of clopidogrel in solution and plasma sample was 
evaluated using two concentration levels (low and high-quality 
control, corresponding to 38.46 and 69.23 µg/ml, respectively). 
The stability of clopidogrel bisulfate was also evaluated in deep 
freezing at-20 ˚C for 12 h. The plasma samples were kept in the 
freezer and after being stressed to 3 freeze-thawing cycles (for 
24 h per cycle). All samples described above were compared to 
freshly prepared clopidogrel bisulfate sample at the same 
concentration levels. 
RESULTS AND DISCUSSION 
Optimization of chromatographic conditions 
The chromatographic conditions were optimized in order to provide a 
good performance of the assay. The mobile phase was selected on the 
basis of its polarity and different trials were taken. Finally, a mobile 
phase consisting acetonitrile, methanol, water (75:20:05 v/v/v) at flow 
rate 1 ml/min was selected. A simple method has been developed as 
mobile phase has not required any buffer and weighing, sonication, 
filtration, adjustment of pH steps (for the preparation of buffer) have 
been eliminated. The retention time of clopidogrel was found to be 4.6 
min. Therefore, the developed method is time-saving and more number 
of samples can be estimated in less time. The chromatogram of 
clopidogrel bisulfate obtained by optimized conditions is shown in fig. 3. 
The optimized chromatographic conditions and system suitability 
parameters are listed in table 1. 
 
Table 1: Optimized chromatographic conditions and system suitability parameters 
S. No. Condition/parameter Details 
1. Column Waters C18 5 µm (4.6 X 250 mm) 
2. Mobile Phase ACN: Methanol: Water (75: 20: 05 v/v/v) 
3. Flow Rate 1.0 ml/min 
4. Retention time 4.6 min 
5. Column Temperature 28 ˚C 
6. Volume of Injection 20 μl 
7. Detection wavelength 225 nm 
8. Theoretical plate 3689.90 
9. Retention time 4.6 
10. Tailing factor 1.35 
 
 
Fig. 2: Chromatogram of blank plasma 
 
 
Fig. 3: Chromatogram of plasma spiked with drug 
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Linearity and range 
The value of R2 was found to be 0.9917, which indicated that the 
developed method is linear in the selected concentration range. The 
developed method is sensitive as the range of this method was found 
from 30.76 to 69.23 µg/ml concentrations of the drug. 
Accuracy 
The mean % recovery of calculated concentrations for all quality 
control samples at LQC, MQC and HQC concentration levels are 
ranged from 103.60 % to 109.80 %, which is within acceptance 
criteria 85.00-115.00 % (table 2). 
Precision 
The % CV of calculated concentrations for all quality control samples 
at LQC, MQC and HQC concentration levels are ranged from 0.196-
1.774 % for intraday and 0.451-1.303 % for interday precision, 
which is within acceptance criteria 15.00 % (table 3). 
 
 
Fig. 4: Calibration curve of clopidogrel bisulfate
 
Table 2: Results of accuracy studies 
S. No. LQC MQC HQC 
Mean (µg/ml)±SD* 39.87±1.148 56.36±1.406 76.06±1.625 
% CV 2.879 2.474 2.137 
Mean % recovery 103.60 105.53 109.80 
*Each value is represented as a mean±SD of 5 observation (n=5), SD: Standard Deviation, CV: Coefficient of Variation 
 
Table 3: Results intraday and interday precision of clopidogrel bisulfate 
Parameter LQC MQC HQC 
Intraday SD 0.683 0.104 0.956 
% CV 1.774 0.196 1.385 
Interday SD 0.511 0.240 0.533 
% CV 1.303 0.451 0.765 
Each value is represented as a mean±SD and % CV of 5 observation (n=5), SD: Standard Deviation, CV: Coefficient of Variation)  
 
Stability studies 
The results of all stability studies are within acceptance criteria 
(table 4). The results of freeze-thaw stability studies suggested that 
clopidogrel bisulfate was stable in human plasma for at least 24 h. 
The results of short-term stability studies indicated that the quality 
control samples were stable for 12 h at-20 ˚C. Similarly, the results 
of stock solution studies confirmed the stability of stock solutions.
  
Table 4: Results of stability studies 
Concentration measured µg/ml 
LOW QC Stock solution (5h) Short term(-20 ˚c,12 h) Freeze-thaw (24 h) 
Mean (µg/ml)±SD* 40.12±0.909 40.03±0.803 37.46±0.755 
%CV 2.267 2.006 2.016 
% Stability 102.34 103.92 95.43 
HIGH-QC    
Mean (µg/ml)±SD* 74.09±2.435 69.92±2.027 65.76±1.900 
%CV 3.286 2.899 2.889 
% Stability 106.40 101.23 94.44 
*Each value is represented as a mean±SD of 3 observation (n=3), SD: Standard Deviation, CV: Coefficient of Variation 
 
CONCLUSION 
The work described in this paper deals with the analysis of clopidogrel 
bisulfate using RP-HPLC method in human plasma. The precision and 
accuracy of the method met the criteria laid down in guidance for 
industry, Bioanalytical method validation, USFDA. Sufficient stability of 
both LQC and HQC was shown to allow for completion of sample analysis 
in clinical trials. From the results, we can conclude that developed 
method is simple, accurate, rapid and precise. Thus, it can be used for 
routine analysis of clopidogrel bisulfate in human plasma. 
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